InvestSMART

4DMedical Limited (ASX: 4DX) - Announcements

Current share price for 4DX : $4.185 0.125 (2.90%)+

ASX company news and announcements for 4DMedical Limited (4DX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All 4DMedical Limited (4DX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than 4DMedical Limited (4DX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for 4DMedical Limited (4DX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,518 4DMedical Investor Conference Presentation - July 2021 26 Jul 2021 8:17AM $1.365 $4.185 risen by 206.59%
$2,518 Quarterly Activity Report and Appendix 4C for Q4 FY2021 26 Jul 2021 8:17AM $1.365 $4.185 risen by 206.59%
$2,518 Application for quotation of securities - 4DX 30 Jun 2021 8:18AM $1.265 $4.185 risen by 230.83%
$2,518 Cleansing Notice 30 Jun 2021 8:18AM $1.265 $4.185 risen by 230.83%
$2,518 4DMedical Tax Exempt Employee Share Plan Rules 30 Jun 2021 8:18AM $1.265 $4.185 risen by 230.83%
$2,518 4DMedical commences XV LVAS clinical trial at Johns Hopkins 29 Jun 2021 8:21AM $1.170 $4.185 risen by 257.69%
$2,518 Notification regarding unquoted securities - 4DX 28 Jun 2021 3:00PM $1.185 $4.185 risen by 253.16%
$2,518 4DMedical receives US$600k order for preclinical scanner 17 Jun 2021 8:50AM $1.270 $4.185 risen by 229.53%
$2,518 Change of interests of substantial holder - Velocimetry & HF 7 Jun 2021 10:28AM $1.310 $4.185 risen by 219.47%
$2,518 Change of interests of substantial holder - AF 7 Jun 2021 10:26AM $1.310 $4.185 risen by 219.47%
$2,518 Change of interests of substantial holder - 4DMedical 7 Jun 2021 10:25AM $1.310 $4.185 risen by 219.47%
$2,518 4DMedical commences patient recruitment for VQ trial 20 May 2021 8:20AM $1.295 $4.185 risen by 223.17%
$2,518 4DMedical partners with RCI for clinical pilot program 28 Apr 2021 8:50AM $1.585 $4.185 risen by 164.04%
$2,518 Quarterly Activity Report and Appendix 4C for Q3 FY2021 26 Apr 2021 8:56AM $1.620 $4.185 risen by 158.33%
$2,518 4DMedical Goldman Sachs Healthcare Forum Presentation 21 Apr 2021 9:33AM $1.610 $4.185 risen by 159.94%
$2,518 Appendix 3Y - BR 12 Apr 2021 2:20PM $1.730 $4.185 risen by 141.91%
$2,518 Appendix 3Y - LG 12 Apr 2021 2:20PM $1.730 $4.185 risen by 141.91%
$2,518 Appendix 3Y - LB 12 Apr 2021 2:19PM $1.740 $4.185 risen by 140.52%
$2,518 Appendix 2A 7 Apr 2021 11:25AM $1.630 $4.185 risen by 156.75%
$2,518 Update - Proposed issue of Securities - 4DX 6 Apr 2021 3:11PM $1.705 $4.185 risen by 145.45%
$2,518 4DMedical raises $6m in strongly supported SPP 31 Mar 2021 4:28PM $1.720 $4.185 risen by 143.31%
$2,518 4DMedical secures streamlined access to US DoD&VA contracts 25 Mar 2021 10:10AM $1.590 $4.185 risen by 163.21%
$2,518 4DMedical to present at NWR virtual investor conference 17 Mar 2021 8:23AM $1.540 $4.185 risen by 171.75%
$2,518 Appendix 3G 15 Mar 2021 2:53PM $1.550 $4.185 risen by 170%
$2,518 Share Purchase Plan Offer Booklet 15 Mar 2021 9:56AM $1.500 $4.185 risen by 179%

501 - 525 of 597 results

Page 21 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.